About the Authors

Julia A. Messina

Affiliations Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, United States of America, Duke Clinical Research Institute, Duke University, Durham, North Carolina, United States of America

Joshua T. Thaden

Affiliation Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, United States of America

Batu K. Sharma-Kuinkel

Affiliation Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, United States of America

Vance G. Fowler Jr.

vance.fowler@duke.edu

Affiliations Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, United States of America, Duke Clinical Research Institute, Duke University, Durham, North Carolina, United States of America

Competing Interests

I have read the journal's policy and have the following conflicts: VGF reports serving as chair of Merck’s V710 scientific advisory committee; receiving grant support and having grants pending from NIH, MedImmune, Actavis/Forest/Cerexa, Pfizer, Cubist/Merck, Advanced Liquid Logics, Theravance, Novartis; serving as a paid consultant for Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Contrafect; personal fees from Royalties (UpToDate), personal fees from payment for development of educational presentations (Green Cross, Cubist, Cerexa, Durata, Theravance), and a patent pending on bacterial diagnostics. This does not alter our adherence to all PLOS policies on sharing data and materials. The other authors have declared that no competing interests exist.